The coronavirus disease (COVID-19) pandemic has caused 2.69 million deaths and 122 million infections. Great efforts have been made worldwide to promptly develop effective vaccines and reduce morbidity and mortality rates from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Available vaccines have proven highly effective at preventing symptomatic disease in clinical trials and real-world reports and are playing an essential role in flattening the epidemiology curve and, mostly, in reducing COVID-19 hospitalizations. Some concerns have been raised after very rare cases of myocarditis and pericarditis recently reported by the Centers for Disease Control and Prevention (CDC) as potentially associated with COVID-19 mRNA vaccinations, namely the Pfizer-BioNTech mRNA vaccine (BNT162b2) and the Moderna mRNA vaccine (mRNA-1273). Therefore, the aim of this document is to explore the possible link between COVID-19 mRNA vaccination and the development of myocarditis and/or pericarditis by performing a critical analysis of available data and to provide indications for specific subgroups of individuals.

Sinagra, G., Porcari, A., Merlo, M., Barillà, F., Basso, C., Matteo Ciccone, M., et al. (2021). Miocarditi, pericarditi e vaccino a mRNA contro il COVID-19. Expert opinion della Società Italiana di Cardiologia. GIORNALE ITALIANO DI CARDIOLOGIA.

Miocarditi, pericarditi e vaccino a mRNA contro il COVID-19. Expert opinion della Società Italiana di Cardiologia

Francesco Barillà;Saverio Muscoli;
2021-11-01

Abstract

The coronavirus disease (COVID-19) pandemic has caused 2.69 million deaths and 122 million infections. Great efforts have been made worldwide to promptly develop effective vaccines and reduce morbidity and mortality rates from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Available vaccines have proven highly effective at preventing symptomatic disease in clinical trials and real-world reports and are playing an essential role in flattening the epidemiology curve and, mostly, in reducing COVID-19 hospitalizations. Some concerns have been raised after very rare cases of myocarditis and pericarditis recently reported by the Centers for Disease Control and Prevention (CDC) as potentially associated with COVID-19 mRNA vaccinations, namely the Pfizer-BioNTech mRNA vaccine (BNT162b2) and the Moderna mRNA vaccine (mRNA-1273). Therefore, the aim of this document is to explore the possible link between COVID-19 mRNA vaccination and the development of myocarditis and/or pericarditis by performing a critical analysis of available data and to provide indications for specific subgroups of individuals.
nov-2021
Pubblicato
Rilevanza nazionale
Articolo
Esperti anonimi
Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE
Italian
Coronavirus; Epidemiology; Myocarditis; Vaccine.
https://pubmed.ncbi.nlm.nih.gov/34709228/
Sinagra, G., Porcari, A., Merlo, M., Barillà, F., Basso, C., Matteo Ciccone, M., et al. (2021). Miocarditi, pericarditi e vaccino a mRNA contro il COVID-19. Expert opinion della Società Italiana di Cardiologia. GIORNALE ITALIANO DI CARDIOLOGIA.
Sinagra, G; Porcari, A; Merlo, M; Barillà, F; Basso, C; Matteo Ciccone, M; Curcio, A; Mancone, M; Mercuro, G; Muscoli, S; Nodari, S; Pedrinelli, R; S...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Miocarditi, pericarditi e vaccino a mRNA contro il covid.pdf

accesso aperto

Licenza: Copyright dell'editore
Dimensione 88.7 kB
Formato Adobe PDF
88.7 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/314480
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 9
social impact